Efficacy and safety of oteseconazole in recurrent vulvovaginal candidiasis (RVVC) – A systematic review and meta-analysis

• Published in: Heliyon 2023-11, Vol.9 (11), p.e20495, Article e20495
• Main Authors: Siddiqui, Tasmiyah, Kumar, Kanwal Ashok, Iqbal, Amna, Doultani, Payal Rani, Ashraf, Tayyaba, Eqbal, Farea, Siddiqui, Samrah Inam
• Format: Article
• Language: English
• Subjects: Fluconazole; Food and drugs administration; Oteseconazole; Vulvovaginal candidiasis (VVC)
• ISSN: 2405-8440; 2405-8440
• DOI: 10.1016/j.heliyon.2023.e20495

Recurrent Vulvovaginal Candidiasis (RVVC) is defined as 3 or more episodes of symptomatic Vulvovaginal Candidiasis (VVC) within a year. Out of 75 % of women with VVC, this debilitating infection is experienced by 9 % of women. Although standard guidelines recommend oral and topical fluconazole as its treatment regimen, approval of another drug Oteseconazole has drawn the attention because of its better safety profile and lower recurrence rate by its use. The purpose of our Meta-analysis is to evaluate the safety and efficacy of Oteseconazole (Vivjoa) (VT-1161) in the treatment of Recurrent Vulvovaginal Candidiasis (RVVC). Four databases namely PubMed, Google Scholar, Cochrane CENTRAL and Clinical Trial.gov were used from inception till June 2023. Studies that met the predefined inclusion criteria were statistically analyzed on RevMan (Version 5.4). A random effect model was used to pool the studies. A p value of less than 0.05 was considered significant and results were presented as Odds ratio with 95 % Confidence Intervals (CIs). The pooled analysis of our selected studies showed that Oteseconazole was associated with significantly reduced incidence of Recurrent Vulvovaginal Candidiasis (OR = 0.07; 95 % CI = 0.05–0.11; p